RE:FDA comments on biomarkers as surrogate endpoints for AATake what the FDA says about obtaining an accelerated approval with a specific cancer therapy and generally apply that to all cancer therapies with predictive and prognostic biomarkers lookiing at an accelerated approval, like ONCY would be with pelareorep.